Regemat3D distributing Biogelx bioprinting inks

Spanish bioprinter manufacturer Regemat3D has entered into an R&D and distribution partnership with Biogelx, a Scotland-based developer of synthetic bioinks. Through the collaboration, Regemat will add Biogelx’s synthetic bioink products to its distribution portfolio and the companies will aim to offer complete bioprinting solutions to researchers across the world.

Since 2011, Regemat3D has provided custom bioprinting solutions to the research market, including the REGEMAT 3D V1 bioprinter. The company has also played an important role in pushing bioprinting research ahead, working with partners around the globe to develop clinical and pre-clinical models for skin regeneration, living tissues and other applications.

In addition to distributing its materials, Regemat3D will work with Biogelx in an R&D capacity to develop a new skin model leveraging the former’s bioprinting technology and the latter’s synthetic biomaterials.

“We are excited to see future tissue models using Biogelx-INKs,” said Sandy Bulloch, Director of Strategic Alliances at Biogelx. “We believe that this strategic partnership will expand the distribution of our novel peptide-based bioink products to new and existing customers worldwide and provide Regemat3D with an extended platform to provide their customers a robust synthetic bioink for use with their very successful range of bioprinters.”

Biogelx was formed as a spinout of the University of Strathclyde. In a short time, it has made a mark on the bioprinting market by introducing synthetic bioprinting materials based on its self-assembling peptide hydrogel technology. Compared to naturally derived bioinks, the synthetic ones can be tuned with more accuracy and have higher repeatability. When printed, the biomimetic inks can support cell growth, signalling and proliferation for various applications.

“Regemat 3D is always seeking out the best 3D bioprinting technologies solutions that the researchers need. We do believe that this new collaboration with Biogelx will open a new opportunity to offer something new and exciting for researchers to enjoy a true combination of consistency, reproducibility and value for money. The two brands together offer something new and exciting for researchers to enjoy a true combination of consistency, reproducibility and value for money. We’re thrilled to be working with Biogelx on this exciting opportunity.” – Said Manuel Figueruela, Regemat3D CEO